These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 11422945)
1. Pathogen inactivation of labile blood products. Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components Transfus Med; 2001 Jun; 11(3):149-75. PubMed ID: 11422945 [No Abstract] [Full Text] [Related]
3. [Can virus safety of blood products be assured?]. Krusius T Duodecim; 1994; 110(13):1227-30. PubMed ID: 7497931 [No Abstract] [Full Text] [Related]
4. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views. Seghatchian J Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230 [TBL] [Abstract][Full Text] [Related]
5. Blood safety and nucleic acid testing in Europe. Laperche S Euro Surveill; 2005 Feb; 10(2):3-4. PubMed ID: 15735316 [No Abstract] [Full Text] [Related]
6. Beyond HIV, HBV and HCV--how to deal with other viruses? Minor PD Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138 [TBL] [Abstract][Full Text] [Related]
7. French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP). Chamfly V Transfus Sci; 1998 Dec; 19(4):333-42. PubMed ID: 10351148 [No Abstract] [Full Text] [Related]
8. JAMA patient page. Avoiding diseases transmitted by blood and body fluids. JAMA; 2000 Jul; 284(2):268. PubMed ID: 10917793 [No Abstract] [Full Text] [Related]
9. [Therapy with blood and blood products]. Kreienbühl G Urologe A; 1996 Jan; 35(1):69-85. PubMed ID: 8851853 [No Abstract] [Full Text] [Related]
10. The role of leukodepletion in the control of transfusion-transmitted disease. Goldman M; Delage G Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040 [No Abstract] [Full Text] [Related]
11. [XMRV is not pathogenic in human and has no significance for the safety of blood and blood products]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Aug; 55(8):1057-60. PubMed ID: 22842897 [No Abstract] [Full Text] [Related]
12. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Corash L Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276 [TBL] [Abstract][Full Text] [Related]
16. [Transfusions of blood and blood products and virus infections]. Wróblewska M; Piotrowska E; ĺuczak M Postepy Hig Med Dosw; 2002; 56(2):221-40. PubMed ID: 12107964 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the leuko-reductive efficacy of single-donor erythropheresis procedures]. Domingo JM; Rabasa P; Chueca P; Medarde A Sangre (Barc); 1999 Jun; 44(3):238-40. PubMed ID: 10481589 [No Abstract] [Full Text] [Related]
18. [Transfusion medicine in unified Europe]. Grigutsch V Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():12-5. PubMed ID: 7841774 [TBL] [Abstract][Full Text] [Related]
19. Safety of the blood supply. Sloand EM; Pitt E; Klein HG JAMA; 1995 Nov; 274(17):1368-73. PubMed ID: 7563562 [No Abstract] [Full Text] [Related]
20. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Blajchman MA Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]